Lipocine (LPCN) Competitors $3.56 +0.25 (+7.55%) Closing price 04:00 PM EasternExtended Trading$3.60 +0.04 (+0.98%) As of 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LPCN vs. ABOS, RENB, INZY, VTVT, RANI, ANRO, MGX, ADAP, VHAQ, and CLSDShould you be buying Lipocine stock or one of its competitors? The main competitors of Lipocine include Acumen Pharmaceuticals (ABOS), Renovaro (RENB), Inozyme Pharma (INZY), vTv Therapeutics (VTVT), Rani Therapeutics (RANI), Alto Neuroscience (ANRO), Metagenomi (MGX), Adaptimmune Therapeutics (ADAP), Viveon Health Acquisition (VHAQ), and Clearside Biomedical (CLSD). These companies are all part of the "pharmaceutical products" industry. Lipocine vs. Acumen Pharmaceuticals Renovaro Inozyme Pharma vTv Therapeutics Rani Therapeutics Alto Neuroscience Metagenomi Adaptimmune Therapeutics Viveon Health Acquisition Clearside Biomedical Lipocine (NASDAQ:LPCN) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, community ranking, dividends, valuation, earnings and profitability. Which has higher valuation & earnings, LPCN or ABOS? Lipocine has higher revenue and earnings than Acumen Pharmaceuticals. Lipocine is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLipocine$11.20M1.70-$16.35M-$0.01-356.00Acumen PharmaceuticalsN/AN/A-$52.37M-$1.71-0.63 Do analysts prefer LPCN or ABOS? Lipocine presently has a consensus target price of $10.00, indicating a potential upside of 180.90%. Acumen Pharmaceuticals has a consensus target price of $7.33, indicating a potential upside of 585.36%. Given Acumen Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Acumen Pharmaceuticals is more favorable than Lipocine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lipocine 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Acumen Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Which has more risk and volatility, LPCN or ABOS? Lipocine has a beta of 1.51, meaning that its share price is 51% more volatile than the S&P 500. Comparatively, Acumen Pharmaceuticals has a beta of 0.1, meaning that its share price is 90% less volatile than the S&P 500. Does the media refer more to LPCN or ABOS? In the previous week, Lipocine had 1 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 3 mentions for Lipocine and 2 mentions for Acumen Pharmaceuticals. Acumen Pharmaceuticals' average media sentiment score of 1.82 beat Lipocine's score of 0.62 indicating that Acumen Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lipocine 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Acumen Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do insiders & institutionals have more ownership in LPCN or ABOS? 9.1% of Lipocine shares are held by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are held by institutional investors. 6.1% of Lipocine shares are held by insiders. Comparatively, 7.1% of Acumen Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community favor LPCN or ABOS? Lipocine received 320 more outperform votes than Acumen Pharmaceuticals when rated by MarketBeat users. However, 72.97% of users gave Acumen Pharmaceuticals an outperform vote while only 66.99% of users gave Lipocine an outperform vote. CompanyUnderperformOutperformLipocineOutperform Votes34766.99% Underperform Votes17133.01% Acumen PharmaceuticalsOutperform Votes2772.97% Underperform Votes1027.03% Is LPCN or ABOS more profitable? Lipocine's return on equity of -19.17% beat Acumen Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets LipocineN/A -19.17% -17.60% Acumen Pharmaceuticals N/A -32.99%-27.99% SummaryAcumen Pharmaceuticals beats Lipocine on 9 of the 17 factors compared between the two stocks. Get Lipocine News Delivered to You Automatically Sign up to receive the latest news and ratings for LPCN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LPCN vs. The Competition Export to ExcelMetricLipocinePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.05M$6.84B$5.53B$7.93BDividend YieldN/A3.05%5.11%4.23%P/E Ratio-4.687.3222.5118.54Price / Sales1.70241.49397.62103.30Price / CashN/A65.8538.1834.62Price / Book0.936.486.734.25Net Income-$16.35M$143.41M$3.22B$248.18M7 Day Performance11.95%2.30%1.58%1.25%1 Month Performance6.27%7.14%4.05%3.76%1 Year Performance-22.94%-2.61%15.75%5.28% Lipocine Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LPCNLipocine2.4862 of 5 stars$3.56+7.6%$10.00+180.9%-28.4%$19.05M$11.20M-4.6810Upcoming EarningsAnalyst ForecastNews CoverageABOSAcumen Pharmaceuticals2.4415 of 5 stars$1.06+17.7%$7.33+591.8%-64.9%$64.21MN/A-0.7720Positive NewsGap DownRENBRenovaro1.3716 of 5 stars$0.40+13.9%N/A-77.2%$63.76MN/A-0.4320Positive NewsINZYInozyme Pharma3.1365 of 5 stars$0.98+6.5%$14.63+1,393.3%-73.9%$62.92MN/A-0.6350Upcoming EarningsNews CoveragePositive NewsVTVTvTv Therapeutics1.7869 of 5 stars$19.67-0.2%$35.50+80.5%-28.5%$62.75M$1.02M-4.349Upcoming EarningsShort Interest ↑News CoverageRANIRani Therapeutics2.4809 of 5 stars$1.09-6.8%$12.33+1,031.5%-82.6%$62.66M$1.03M-1.03110Upcoming EarningsANROAlto Neuroscience1.8333 of 5 stars$2.31+2.2%$15.40+566.7%-84.1%$62.54MN/A-0.91N/AMGXMetagenomi1.4909 of 5 stars$1.67+9.9%$13.00+678.4%-75.4%$62.43M$52.30M-0.64236News CoverageADAPAdaptimmune Therapeutics3.4347 of 5 stars$0.24+1.7%$1.83+655.6%-76.7%$62.30M$178.03M-1.10490Analyst ForecastShort Interest ↓Positive NewsGap DownVHAQViveon Health AcquisitionN/A$11.00flatN/AN/A$62.26MN/A0.002High Trading VolumeCLSDClearside Biomedical2.052 of 5 stars$0.80-7.0%$5.25+556.3%-31.3%$61.82M$1.66M-1.7830Upcoming EarningsNews CoverageGap Up Related Companies and Tools Related Companies ABOS Alternatives RENB Alternatives INZY Alternatives VTVT Alternatives RANI Alternatives ANRO Alternatives MGX Alternatives ADAP Alternatives VHAQ Alternatives CLSD Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LPCN) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredWhat if America bought gold like it used to?History Says Gold Wins When This Signal Flashes — and It’s Flashing Now Every time the Buffett Indicator ha...Golden Portfolio | SponsoredMassive dollar overhaul underway in D.C.?Trump's plan to save the U.S. Dollar The U.S. Dollar is crashing, and our reserve currency status is now in...Stansberry Research | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lipocine Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lipocine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LPCN Stock Free LPCN Stock Alerts